Investigators examined survival outcomes and recurrence patterns by pathologic nodal status in patients with upper tract urothelial carcinoma (UTUC) receiving neoadjuvant chemotherapy.

Tislelizumab combined with chemotherapy shows promising antitumor activity in advanced cervical cancer, achieving high response rates and manageable safety profiles.

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Adding stereotactic ablative radiotherapy (SAbR) to neoadjuvant chemotherapy improves pathologic outcomes for patients ...

Upper GI cancer treatment depends on a number of factors, and may include treatments such as surgery, chemotherapy, radiation ...

Total neoadjuvant therapy demonstrates consistent real-world efficacy across regimens in patients with locally advanced ...

Announcing a new article publication for BIO Integration journal. Imbalances in the intestinal microbiome are closely ...

US-based PanTher Therapeutics has initiated a trial of its chemotherapy-eluting patch, which it hopes will make cancer therapy more tolerable. The Phase Ib study (NCT06673017) is investigating PTM-101 ...

Cambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) ...

Fewer than half of eligible patients with advanced ovarian cancer receive first-line maintenance treatments, highlighting ...